$FEMY

Elefant Dov purchased $50K of FEMY

Elefant Dov (Chief Financial Officer) purchased 15,625 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.

Original reporting
SEC EDGAR · Elefant Dov
Published Aug 12, 2026, 12:37 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FEMY
Neutral
low confidence
Mentioned
$FEMY
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FEMYNeutralLow
01

Why it matters

This is a primary-source insider buy, but it does not include guidance, earnings, contracts, litigation, or other fundamental updates.

02

Market read

Traders may note insider buying as a small sentiment input, but there is no new fundamental driver in the text.

03

What to watch

The article does not state whether the CFO’s purchase was funded by compensation, options exercises, or other liquidity events, limiting interpretability.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-08-11, covering a purchase dated 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for FEMASYS Inc (FEMY).

Company-level read

Ticker impact

$FEMYNeutralLow confidence
Context

FEMASYS CFO Elefant Dov bought 15,625 shares at $3.20 on 2026-08-07, disclosed via Form 4 filed 2026-08-11.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven rather than a re-rating catalyst.

Evidence & confidence

Form 4 insider purchases can be informative, but this disclosure provides no new company-specific operational or financial information, and the size is relatively small.

Market effects

None indicated; this is a single-company insider transaction with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or planned; the filing explicitly notes no pre-arranged 10b5-1 plan, but that still does not confirm conviction or timing advantage.

Key entities

  • FEMASYS Inc

    Company whose CFO insider purchase is disclosed on Form 4.

  • Elefant Dov

    Chief Financial Officer who purchased shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$FEMYMed

FEMASYS INC (FEMY): Results of Operations and Financial Condition

FEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr

$FEMYMedAI 8/10

Femasys Stock Falls 11% Over Announcement Of $30 Mln Private Placement

Femasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.

$FEMYMedAI 8/10

Femasys Inc.: Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

Femasys Inc. (NASDAQ: FEMY) said it entered a $30 million private placement with accredited investors led by Nantahala Capital, with participation from other healthcare funds and management. It will sell 9,374,999 shares plus pre-funded and accompanying warrants. If all warrants are exercised, Femasys could receive up to $60 million more. Closing is expected around Aug. 10, 2026.